Credo Technology Group's $40M Insider Sales Cap Upside in an Already Expensive AI Story

Key Takeaways

• Credo Technology Group (CRDO) C-suite executives sold over $40 million in shares in July 2026, a significant de-risking move despite these sales being executed under pre-planned 10b5-1 programs.
• While CRDO's FY2026 revenue grew 206% and FY2027 guidance remains robust, the stock's rich ~66x trailing non-GAAP earnings multiple increases its vulnerability to sentiment shifts and any potential execution risks in its back-half optical ramp.
• This persistent supply overhang from insider selling, combined with ambitious future growth expectations, is likely to constrain CRDO within a $200-$275 range until the September 2, 2026 earnings report validates its aggressive growth trajectory.

A Wave of C-Suite Selling Breaks the Silence

Credo Technology Group (CRDO), a high-flying provider of AI data center connectivity solutions, saw substantial open-market share sales by its Chief Operating Officer (COO) Lam Yat Tung and Chief Technology Officer (CTO) Chi Fung (Lawrence) Cheng in July 2026. These transactions, all executed under pre-established Rule 10b5-1 trading plans, collectively topped $40 million. The activity comes at a pivotal moment for CRDO, which has delivered explosive growth but now trades at a premium valuation as it navigates an ambitious transition to optical connectivity. For investors, the question is whether these insider sales signal a strategic de-risking by executives or hint at a looming slowdown not yet reflected in public guidance.

COO Lam Yat Tung's sales alone surpassed $35 million in July. On July 15, 2026, he sold 55,998 shares at a weighted average price of $225.44, generating $12.6 million. Just over two weeks later, on July 31, he disposed of an additional 105,441 shares across 14 tranches, with prices ranging from $209.83 to $216.49, bringing in approximately $22.48 million. CTO Chi Fung (Lawrence) Cheng also contributed to the selling, with his family trust executing sales of 27,500 shares on July 27, 2026, at prices between $197.94 and $218.79, totaling $5.65 million. In aggregate, these C-suite sales reached approximately $40.73 million, concentrated in a trading range of $197 to $225.

These dispositions occurred as CRDO’s stock, currently trading at $229.84 as of August 5, 2026, pulled back significantly from its 52-week high of $308.67 set on June 22, 2026. This means insiders were selling even after a roughly 25% correction from peak prices, rather than exclusively at all-time highs. While the timing of such sales is often attributed to personal diversification, their sheer magnitude and the executives' continued retention of multi-million dollar holdings suggest a complex interplay of personal financial planning, valuation considerations, and the company's ambitious future trajectory. The market's interpretation of this activity could be a key determinant of CRDO's short-term price action, particularly ahead of its crucial Q1 FY2027 earnings report scheduled for September 2, 2026.

What the Numbers Actually Say

Credo Technology Group’s recent financial performance has been nothing short of exceptional, showcasing robust growth and profitability. For fiscal year 2026, which ended May 2, 2026, the company reported revenue of $1.335 billion, an impressive 206% increase year-over-year. This explosive growth was paired with strong profitability, as non-GAAP net income reached $662 million, more than five times the previous year’s figure, translating to non-GAAP diluted earnings per share of $3.46.

The fourth quarter of fiscal year 2026 also demonstrated continued momentum, with revenue of $437.0 million, marking a 7.4% sequential increase from Q3 FY2026. Margins remained robust, with non-GAAP gross margin holding at a high 68.3% and non-GAAP operating margin reaching an impressive 49.6%. Crucially, Credo generated record free cash flow of $177.5 million in Q4 FY2026, underscoring its capital-light model and operational efficiency. The company also ended the fiscal year with a substantial cash and short-term investments balance of $1.4 billion.

Looking ahead, management’s guidance for Q1 FY2027 anticipates continued top-line expansion, projecting revenue between $465 million and $475 million. The midpoint of this guidance, $470 million, implies a sequential growth of 7.6% from Q4 FY2026. Non-GAAP gross margin is expected to remain strong at 67.0% to 69.0%. While these figures attest to Credo’s strong fundamental trajectory, the market is pricing in exceptional growth. At its current price of $229.84, CRDO trades at roughly 66.4 times its trailing non-GAAP FY2026 EPS. This rich valuation suggests that investors are heavily discounting future growth, with analysts forecasting revenue to more than triple to $5.1 billion by FY2030, implying a compound annual growth rate of over 40% from FY2026 levels.

Scheduled Diversification, Not Panic

The substantial C-suite sales at Credo Technology Group in July 2026, while grabbing headlines, are primarily attributable to pre-arranged Rule 10b5-1 trading plans. These plans allow corporate insiders to sell a predetermined number of shares at a predetermined time or price, providing an affirmative defense against accusations of insider trading. This structural element significantly limits the interpretability of these sales as real-time negative sentiment.

CTO Chi Fung (Lawrence) Cheng’s sales, for instance, were executed under a Rule 10b5-1 plan adopted by the Cheng Huang Family Trust as far back as September 5, 2025. This plan authorizes the sale of up to 1,000,000 shares between January 2, 2026, and December 31, 2026. Similarly, COO Lam Yat Tung’s plan was adopted on April 15, 2026, allowing for sales of up to 511,439 shares between July 15, 2026, and January 15, 2027. Both executives explicitly stated in their SEC Form 4 filings that the sales were "effected pursuant to a Rule 10b5-1 trading plan."

Despite the considerable dollar value of the sales, these transactions represent a relatively modest percentage of the executives' total holdings. After his July sales, COO Lam Yat Tung still retains over 2.5 million direct shares and 525,000 indirect shares. CTO Cheng, through his family trust, maintains nearly 5.8 million indirect shares and 140,358 direct shares. These substantial remaining stakes, collectively representing approximately 4.73% of shares outstanding, suggest that the insiders are not signaling a full exit or a loss of faith in the company's long-term prospects. Instead, the pattern aligns with systematic wealth diversification, a common practice for executives whose net worth is heavily concentrated in company stock after significant appreciation.

Moreover, Credo’s corporate governance guidelines, updated in March 2026, require non-CEO executive officers to hold equity equal to one times their base salary within four years. Given their multi-million share positions, both Lam and Cheng significantly exceed these thresholds. This further weakens the argument that governance constraints would limit future disposals, as they have ample room to continue selling shares under existing or new 10b5-1 plans without falling out of compliance.

The Back-Weighted Gamble on Optical Growth

Credo Technology Group’s ambitious growth narrative for fiscal year 2027 is heavily back-weighted, with management explicitly outlining a path that depends on a significant second-half inflection driven by its optical portfolio. This strategy, while potentially lucrative, introduces a notable element of execution risk in the short to medium term. Chief Financial Officer Dan Fleming stated on the Q4 FY2026 earnings call that "The first half will see mid-single-digit growth driven by our current portfolio, mainly AECs. The second half will see an inflection driven by our optical portfolio, including Zero Flap Optics, silicon photonics, and optical DSPs."

The Q1 FY2027 revenue guidance of $465 million to $475 million (midpoint $470 million) implies a modest sequential growth of approximately 7.6% from Q4 FY2026's $437 million. To achieve the projected full-year FY2027 revenue growth of over 80% to at least $2.4 billion, Credo will need to significantly accelerate its top-line performance in the latter half of the fiscal year. This acceleration hinges on the successful ramp-up of its optical solutions, with management anticipating each of its three new optical segments – ZeroFlap optics, optical DSPs, and silicon photonics platforms – to contribute over $100 million in revenue. The total optical revenue is expected to exceed $600 million for FY2027.

This reliance on a back-half ramp means that any delays in product qualification, manufacturing capacity, or customer adoption for the new optical offerings could lead to a substantial shortfall against guidance. Given the current rich valuation multiples, even a slight deceleration from these aggressive growth targets could prompt a disproportionate market reaction. While CEO William Brennan conveyed confidence that "All three segments are expected to grow significantly, each contributing more than 80% year-over-year," the market will scrutinize the Q1 FY2027 report for tangible signs of progress towards this back-loaded optical inflection. The potential for such execution risk, when layered with ongoing insider selling, may encourage investors to adopt a more cautious stance until clear evidence of the optical ramp materializes.

The Bear Case Nobody Wants to Own

Despite Credo’s compelling growth story, several risk factors contribute to a bear case that investors should acknowledge, particularly in the wake of significant insider selling.

First, customer concentration presents a substantial vulnerability. In Q4 FY2026, Credo’s top four customers collectively accounted for approximately 87% of its revenue. The largest single customer represented 34% of sales. At FY2026 revenue of $1.335 billion, this implies roughly $454 million from the largest client. Any pause or reduction in spending from even one major hyperscaler could significantly impact Credo’s financial performance, potentially leading to a double-digit percentage decline in revenue and a sharp repricing of the stock.

Second, valuation risk remains elevated. Trading at approximately 66.4 times its trailing non-GAAP FY2026 EPS of $3.46, CRDO carries a premium multiple. While this is partially justified by its high growth, it leaves little room for error. If CRDO’s trailing price-to-earnings multiple were to normalize to, for example, 40 times, the share price would fall to roughly $138, representing a 40% downside from current levels. Even if we consider an implied FY2027 EPS of around $6.03 (derived from management’s guidance), a 30x multiple still yields a price of approximately $181, which is over 21% below the current price. Such multiple compression is plausible if growth decelerates or execution falters.

Finally, the persistent supply overhang from insider selling continues to weigh on sentiment. Even after the July 2026 sales, COO Lam Yat Tung’s 10b5-1 plan still has capacity for roughly 350,000 additional shares through January 2027. CTO Cheng’s plan, adopted earlier, has even more headroom, allowing for hundreds of thousands of shares to be sold through the end of 2026. This ongoing potential for large, programmatic sales creates a mechanical drag on the stock price, potentially capping rallies as new supply enters the market. The consistent absence of insider purchases over the past six months, alongside these sales, reinforces the signal that executives prefer liquidity at current elevated levels.

Wall Street's Split Verdict

Wall Street analysts remain broadly optimistic on Credo Technology Group, despite the recent wave of C-suite insider selling. The consensus rating from 15 analysts is a "Buy," with 13 firms maintaining a Buy rating and only two holding a Neutral or "Hold" stance. There are no Sell or Strong Sell ratings, underscoring the Street's overall confidence in CRDO's long-term growth trajectory in the AI infrastructure space.

The average 12-month price target for CRDO stands at $274.18, with a median target of $275.00. This implies an upside of approximately 19.3% to 19.6% from the current price of $229.84. However, the dispersion in targets is quite wide, ranging from a low of $200.00 to a high of $350.00. This $150 spread, representing about 55% of the current share price, signals a notable divergence in analyst opinion regarding the stock’s ultimate potential and the risks involved.

It's notable that recent rating changes, such as Barclays raising its target to $300 and Susquehanna to $250 in late July 2026, occurred concurrently with or shortly after initial insider sale disclosures. This suggests that, at least for some analysts, the insider activity has been viewed as a secondary factor to the company’s strong fundamentals and AI-driven tailwinds. The low target of $200.00 provides a potential floor, representing a 13.0% downside from the current price. Conversely, the high target of $350.00 implies over 50% upside, indicating that some analysts envision a continued re-rating as CRDO executes on its optical growth strategy. The wide target dispersion points to heightened uncertainty and a market grappling with how to reconcile exceptional growth potential with premium valuation and visible insider de-risking.

Weighing the Strongest Objection

The most compelling argument against a cautious short-term view on CRDO is that the July 2026 C-suite insider sales, being executed under pre-planned Rule 10b5-1 programs, are merely systematic diversification and therefore carry little informational content about management's real-time sentiment or the company’s near-term prospects. Proponents of this view correctly point out that executives retain vast holdings, with the dollar value of sales representing a small fraction of their total economic exposure to Credo. Furthermore, the stock exhibited resilience, recovering sharply from a nearly 25% peak-to-trough drawdown in July to return to pre-sale levels within three weeks. This rapid recovery suggests underlying market strength and investor belief in the AI story, effectively shrugging off the "insider selling" narrative.

However, this argument, while valid in part, does not entirely dislodge the short-term overhang. While 10b5-1 plans provide a legal defense, academic studies have shown that sales under such plans can still be modestly informative, often preceding periods of mild underperformance. More crucially, the sheer magnitude and clustering of these sales—over $40 million from both the COO and CTO in a single month—is conspicuous, even if pre-planned. This volume, combined with significant remaining capacity under existing 10b5-1 plans (hundreds of thousands of shares), suggests a persistent, mechanical supply that can cap rallies.

The recovery observed in late July and early August, while strong, occurred during a broader rebound in AI-related stocks. It does not negate the potential for future sales to exert pressure, especially if the wider market turns less favorable. The core tension is not whether insiders are signaling an imminent collapse, but whether their strategic de-risking at current rich valuations will dampen enthusiasm and create a lower ceiling for the stock in the near term.

My thesis narrows to this: the pre-planned nature and retained holdings are mitigating factors, but the combination of large-scale insider sales at a high valuation (roughly 66x trailing non-GAAP EPS), significant remaining selling capacity, and a back-weighted, ambitious optical growth narrative means that CRDO’s short-term upside is likely to be capped. The market now requires unequivocal execution on the company's Q1 FY2027 guidance and a clearer path to its second-half optical ramp to drive sustained gains beyond the $275 consensus target.

The figure that will decide this debate is Credo's Q1 FY2027 revenue and updated guidance, which will be reported on September 2, 2026. If the company delivers sequential revenue growth notably above its mid-single-digit guidance and provides credible evidence of its optical portfolio ramp, the benign "diversification" argument will gain significant strength. Conversely, any miss or deceleration will retroactively amplify concerns that insiders were de-risking ahead of a more challenging growth environment.

The Verdict on Credo's AI Premium

Credo Technology Group (CRDO) presents a fascinating dilemma: a high-growth company at the forefront of the AI infrastructure boom, offset by significant C-suite insider selling into a premium valuation. While the company's fundamentals remain exceptionally strong, with 206% revenue growth in FY2026 and robust profitability, the concentrated $40 million in July 2026 insider sales, though pre-planned, cannot be ignored. These sales, combined with CRDO's roughly 66x trailing non-GAAP earnings multiple and a back-weighted FY2027 growth strategy, are likely to cap short-term upside and amplify volatility.

My stance on CRDO for the near term (next 1-3 quarters) is Neutral to Cautious. The long-term AI narrative for Credo is intact, but its rich valuation and the persistent supply overhang from planned insider selling make it susceptible to outsized reactions to any growth decelerations or execution missteps.

• Entry Zone: Investors seeking to enter should consider accumulating shares in the $200-$215 range, aligning with the low end of analyst targets and the upper bound of recent insider sale prices, which may act as a near-term psychological support.
• 12-Month Target: A 12-month target of $260-$275 is reasonable, reflecting a modest appreciation that acknowledges the growth story but factors in the selling pressure and potential for multiple compression. This target is below the current consensus but represents roughly 13-20% upside from today's price.
• Invalidation Level: A sustained break below $177 (the July 29, 2026 trough) or a significant miss on Q1 FY2027 revenue and a downward revision to its FY2027 optical ramp guidance would invalidate this thesis, suggesting a more fundamental challenge beyond mere sentiment.

The true test for Credo lies in its ability to execute on its ambitious back-half FY2027 optical growth. Until the September 2, 2026 earnings report and subsequent guidance provide clear validation, CRDO shares are likely to remain range-bound, oscillating between the gravitational pull of insider de-risking and the undeniable promise of AI infrastructure.

---

Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.